No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257 3262. 308. el-Agroudy AE, Hassan NA, Foda MA et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003; 23: 300 306. 309. Philipp T, Martinez F, Geiger H et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25: 967 976. 310. Knoll GA, Cantarovitch M, Cole E et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design. Nephrol Dial Transplant 2008; 23: 354 358. 311. Ardissino G, Vigano S, Testa S et al. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplas- tic nephropathy report from the ItalKid Project database. Nephrol Dial Transplant 2007; 22: 2525 2530. 312. Flynn JT, Mitsnefes M, Pierce C et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52: 631 637. 313. Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal insufficiency in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 2003; 14: 2618 2622. 314. Sinha R, Saad A, Marks SD. Prevalence and complications of chronic kidney disease in paediatric renal transplantation: a K/DOQI perspective. Nephrol Dial Transplant 2010; 25: 1313 1320. 315. Wong H, Mylrea K, Feber J et al. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 2006; 70: 585 590. 316. 